Additional cytogenetic changes an predict unfavorable prognosis in and acute myelold leukemia previous genotoxic exposure myelodysplastic syndromes with der(1;7)(q10;p10)

被引:14
作者
Hsiao, HH
Sashida, G
Ito, Y
Kodama, A
Fukutake, K
Ohyashiki, JH
Ohyashiki, K
机构
[1] Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan
[2] Tokyo Med Univ, Cent Lab, Chromosome Unit, Shinjuku Ku, Tokyo 1600023, Japan
[3] Tokyo Med Univ, Intractable Immune Syst Res Ctr, Shinjuku Ku, Tokyo 1600023, Japan
[4] Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung 807, Taiwan
关键词
D O I
10.1016/j.cancergencyto.2005.09.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We analyzed 23 patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) showing a der(1;7)(q10;p10) [hereafter der(1;7)] to identify the exact predictive factor of this cytogenetic change. Eight (34.8%) patients, including six with MDS and two with AML patients, had a previous history of genotoxic exposure, especially radiation and/or antimetabolites. Patients with der(1;7) consisted of three groups: one third of patients had a previous history of genotoxic agents, one third had additional cytogenetic changes at the time of MDS/AML diagnosis without previous exposure history, and the remaining one third had neither a previous exposure history nor additional cytogenetic changes. The current study demonstrated that the poor outcome of MDS/AML with der(1;7) is Caused by the high frequency of associated risk factors (i.e., previous history of genotoxic exposure, the presence of additional cytogenetic changes, or both). Identification of prognostic disadvantage might be required for applying the appropriate strategy in managing MDS/AML patients with rare der(1;7) abnormality. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 26 条
[1]   Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere [J].
Andersen, MK ;
Pedersen-Bjergaard, J .
LEUKEMIA, 2000, 14 (01) :105-111
[2]   Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: Report from an international workshop [J].
Block, AW ;
Carroll, AJ ;
Hagemeijer, A ;
Michaux, L ;
van Lom, K ;
Olney, HJ ;
Baer, MR .
GENES CHROMOSOMES & CANCER, 2002, 33 (04) :401-412
[3]   AN IDENTICAL TRANSLOCATION BETWEEN CHROMOSOME-1 AND CHROMOSOME-7 IN 3 PATIENTS WITH MYELOFIBROSIS AND MYELOID METAPLASIA [J].
GERAEDTS, JPM ;
OTTOLANDER, GJD ;
PLOEM, JE ;
MUNTINGHE, OG .
BRITISH JOURNAL OF HAEMATOLOGY, 1980, 44 (04) :569-575
[4]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088
[5]  
HORIIKE S, 1990, CANCER, V65, P1350, DOI 10.1002/1097-0142(19900315)65:6<1350::AID-CNCR2820650617>3.0.CO
[6]  
2-J
[7]   De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia [J].
Hsiao, HH ;
Ito, Y ;
Sashida, G ;
Ohyashiki, JH ;
Ohyashiki, K .
LEUKEMIA RESEARCH, 2005, 29 (11) :1247-1252
[8]  
LeBeau MM, 1996, BLOOD, V88, P1930
[9]   The prognostic impact of karyotypic subgroups in myelodysplastic syndromes is strongly modified by sex [J].
Mauritzson, N ;
Johansson, B ;
Rylander, L ;
Albin, M ;
Strömberg, U ;
Billström, R ;
Ahlgren, T ;
Mikoczy, Z ;
Mitelman, F ;
Hagmar, L ;
Nilsson, PG .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) :347-356
[10]   Molecular features of primary MDS with cytogenetic changes [J].
Mecucci, C .
LEUKEMIA RESEARCH, 1998, 22 (04) :293-302